CSF-T-tau levels in the total patient cohort correlated with age at disease onset (r = 0.71, p = 0.0003), GAD positivity (r = 0.47, p = 0.03), NMDAR positivity (r= −0.56, p = 0.008), bradykinesia (r = 0.52, p = 0.02), dysdiadochokinesia (r = 0.47, p = 0.03), weight loss (r = 0.48, p = 0.03), peripheral neuropathy (r = 0.46, p = 0.04), tumor presence (r = 0.47, p = 0.03), partial recovery (regarding disease evolution) (r = −0.53, p = 0.04) and death (r = 0.66, p = 0.008) (independent correlations, not correction for multiple parameters). The gene discussed is GAD1; the disease is peripheral neuropathy.